{"name":"Genmab","slug":"genmab","ticker":"GMAB","exchange":"NASDAQ","domain":"genmab.com","description":"Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.","hq":"Copenhagen, Denmark","founded":1999,"employees":"2973","ceo":"Jan van de Winkel","sector":"Oncology / Immunology Biotech","stockPrice":28.05,"stockChange":0.4,"stockChangePercent":1.45,"marketCap":"$17.3B","metrics":{"revenue":3720000000,"revenueGrowth":3,"grossMargin":93.6,"rdSpend":0,"netIncome":963000000,"cash":1715000064,"dividendYield":0,"peRatio":18.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2023-01-01","label":"Epkinly first approved","drug":"Epkinly","drugSlug":"epcoritamab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-01","label":"EPKINLY Phase 3 readout (Diffuse Large B-Cell Lymphoma)","drug":"EPKINLY","drugSlug":"epcoritamab-bysp","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-04-01","label":"EPKINLY Phase 3 readout (Diffuse Large B-cell Lymphoma)","drug":"EPKINLY","drugSlug":"epcoritamab-bysp","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-14","label":"EPKINLY Phase 3 readout (Diffuse Large B-Cell Lymphoma)","drug":"EPKINLY","drugSlug":"epcoritamab-bysp","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-01-01","label":"Epkinly PHASE1,PHASE2 readout","drug":"Epkinly","drugSlug":"epcoritamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2037-11-01","label":"EPKINLY Phase 3 readout (Follicular Lymphoma (FL))","drug":"EPKINLY","drugSlug":"epcoritamab-bysp","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Doxorubicin Hydrochloride [HCl] patent cliff ($1.4B at risk)","drug":"Doxorubicin Hydrochloride [HCl]","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Epcoritamab patent cliff ($1.1B at risk)","drug":"Epcoritamab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Epkinly","genericName":"EPCORITAMAB","slug":"epcoritamab","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"marketed"},{"name":"Rina-S","genericName":"Rina-S","slug":"rina-s","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Doxorubicin Hydrochloride [HCl]","genericName":"Doxorubicin Hydrochloride [HCl]","slug":"doxorubicin-hydrochloride-hcl","indication":"Hodgkin's lymphoma","status":"phase_2"},{"name":"EPKINLY","genericName":"EPCORITAMAB-BYSP","slug":"epcoritamab-bysp","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"marketed"},{"name":"Investigator's Choice Chemotherapy","genericName":"Investigator's Choice Chemotherapy","slug":"investigator-s-choice-chemotherapy","indication":"Variable depending on investigator selection; typically used as a control arm in Phase 3 oncology trials","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"rituximab, ifosfamide, carboplatin, and etoposide phosphate","genericName":"rituximab, ifosfamide, carboplatin, and etoposide phosphate","slug":"rituximab-ifosfamide-carboplatin-and-etoposide-phosphate","indication":"Other","status":"phase_1"},{"name":"GEN1079","genericName":"GEN1079","slug":"gen1079","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Epkinly","genericName":"EPCORITAMAB","slug":"epcoritamab","phase":"marketed","mechanism":"Epkinly works by binding to the T-cell surface glycoprotein CD3, which is a key component of the T-cell receptor complex.","indications":["Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Rina-S","genericName":"Rina-S","slug":"rina-s","phase":"phase_3","mechanism":"Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"rituximab, ifosfamide, carboplatin, and etoposide phosphate","genericName":"rituximab, ifosfamide, carboplatin, and etoposide phosphate","slug":"rituximab-ifosfamide-carboplatin-and-etoposide-phosphate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Doxorubicin Hydrochloride [HCl]","genericName":"Doxorubicin Hydrochloride [HCl]","slug":"doxorubicin-hydrochloride-hcl","phase":"phase_2","mechanism":"Topoisomerase II inhibitor","indications":["Hodgkin's lymphoma","Breast cancer","Lung cancer"],"catalyst":""},{"name":"EPKINLY","genericName":"EPCORITAMAB-BYSP","slug":"epcoritamab-bysp","phase":"marketed","mechanism":"B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3","indications":["Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"GEN1079","genericName":"GEN1079","slug":"gen1079","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Investigator's Choice Chemotherapy","genericName":"Investigator's Choice Chemotherapy","slug":"investigator-s-choice-chemotherapy","phase":"phase_3","mechanism":"Investigator's Choice Chemotherapy refers to a flexible treatment approach where the investigating physician selects from approved chemotherapy regimens based on patient and tumor characteristics.","indications":["Variable depending on investigator selection; typically used as a control arm in Phase 3 oncology trials"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Genmab Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Genmab reported its fourth quarter and full year 2023 financial results, with revenue of $1.4 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Genmab and Sanofi Announce Collaboration to Develop and Commercialize Epcoritamab","summary":"Genmab and Sanofi announced a collaboration to develop and commercialize epcoritamab, a bispecific antibody for the treatment of non-Hodgkin lymphoma.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Genmab Announces Positive Interim Results from Phase 1 Trial of Epcoritamab in Combination with Pembrolizumab","summary":"Genmab announced positive interim results from a phase 1 trial of epcoritamab in combination with pembrolizumab for the treatment of non-Hodgkin lymphoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"pipeline","source":"simplywall.st","summary":"Genmab Ownership Shift Highlights Orbis Influence And Valuation Debate - simplywall.st","headline":"Genmab Ownership Shift Highlights Orbis Influence And Valuation Debate","sentiment":"neutral"},{"date":"2026-04-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-04-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-27","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[{"drugName":"Doxorubicin Hydrochloride [HCl]","drugSlug":"doxorubicin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Epcoritamab","drugSlug":"epcoritamab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":7,"phaseCounts":{"marketed":2,"phase_3":2,"phase_1":2,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Roche Holding","Merck & Co."],"therapeuticFocus":["Oncology","Immunology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":28.05,"previousClose":27.65,"fiftyTwoWeekHigh":35.43,"fiftyTwoWeekLow":17.23,"fiftyTwoWeekRange":"17.235 - 35.43","fiftyDayAverage":28.91,"twoHundredDayAverage":28.16,"beta":0.74,"enterpriseValue":5414765568,"forwardPE":15.9,"priceToBook":2.96,"priceToSales":4.66,"enterpriseToRevenue":1.46,"enterpriseToEbitda":4.2,"pegRatio":1.75,"ebitda":1290000000,"ebitdaMargin":34.7,"freeCashflow":1068124992,"operatingCashflow":1186000000,"totalDebt":5425999872,"debtToEquity":92.8,"currentRatio":2.02,"returnOnAssets":8.1,"returnOnEquity":17.5,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":37.14,"targetHighPrice":48,"targetLowPrice":24.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":12.1,"sharesOutstanding":613910580,"floatShares":60889434,"sharesShort":8899874,"shortRatio":4.87,"shortPercentOfFloat":1.5,"epsTrailing":1.54,"epsForward":1.77,"revenuePerShare":5.99,"bookValue":9.49,"officers":[{"age":64,"name":"Dr. Jan G.J. van de Winkel Ph.D.","title":"Co-Founder, President & CEO"},{"age":47,"name":"Mr. Anthony  Pagano CPA","title":"Executive VP & CFO"},{"age":57,"name":"Mr. Rayne  Waller","title":"Executive VP & Chief Technical Operations Officer"},{"age":54,"name":"Mr. Gregory David Emil Mueller","title":"Executive VP, General Counsel & Chief Legal Officer"},{"age":46,"name":"Mr. Christopher  Cozic","title":"Executive VP & Chief People Officer"},{"age":54,"name":"Dr. Martine J. van Vugt Ph.D.","title":"Executive VP & Chief Strategy Officer"},{"age":50,"name":"Mr. Martin  Schultz","title":"Senior Director, Head of Development Business Partnership & Strategy and Director"},{"age":67,"name":"Dr. Judith V. Klimovsky M.D.","title":"Executive VP & Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"http://ir.genmab.com/index.cfm","website":"https://www.genmab.com","phone":"45 70 20 27 28"}}